Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Taftachi, R.; Ayhan, Ayşe; Ekici, Sinan; Ergen, Ali; Özen, Haluk

doi:10.1111/j.1464-410x.2005.05356.x

Cited by 33 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, 224 nmol lycopene/g diet (P = 0.05), castration (P = 0.05), 5:5 combination (P = 0.05), tomato (P = 0.001), 10:10 combination (P = 0.001), and broccoli (P = 0.0001) were all associated with suppressed proliferation rates, roughly in parallel with tumor growth. Proliferative index using PCNA has been proposed as a prognostic factor in human prostate cancer, and has been associated with a higher risk of aggressive disease (47). Sulforaphane decreased PCNA in F3II mammary carcinoma implants in BALB/C mice (48), but no reports are available on the effects of broccoli on PCNA in prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas

et al. 2007

View full text Add to dashboard Cite

The consumption of diets containing 5 to 10 servings of fruits and vegetables daily is the foundation of public health recommendations for cancer prevention, yet this concept has not been tested in experimental models of prostate cancer. We evaluated combinations of tomato and broccoli in the Dunning R3327-H prostate adenocarcinoma model. Male Copenhagen rats (n = 206) were fed diets containing 10% tomato, 10% broccoli, 5% tomato plus 5% broccoli (5:5 combination), 10% tomato plus 10% broccoli (10:10 combination) powders, or lycopene (23 or 224 nmol/g diet) for f22 weeks starting 1 month prior to receiving s.c. tumor implants. We compared the effects of diet to surgical castration (2 weeks before termination) or finasteride (5 mg/kg body weight orally, 6 d/wk). Castration reduced prostate weights, tumor areas, and tumor weight (62%, P < 0.001), whereas finasteride reduced prostate weights (P < 0.0001), but had no effect on tumor area or weight. Lycopene at 23 or 224 nmol/g of the diet insignificantly reduced tumor weights by 7% or 18%, respectively, whereas tomato reduced tumor weight by 34% (P < 0.05). Broccoli decreased tumor weights by 42% (P < 0.01) whereas the 10:10 combination caused a 52% decrease (P < 0.001). Tumor growth reductions were associated with reduced proliferation and increased apoptosis, as quantified by proliferating cell nuclear antigen immunohistochemistry and the ApopTag assay. The combination of tomato and broccoli was more effective at slowing tumor growth than either tomato or broccoli alone and supports the public health recommendations to increase the intake of a variety of plant components. [Cancer Res 2007;67(2):836-43]

show abstract

Section: Discussionmentioning

confidence: 99%

Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas

et al. 2007

View full text Add to dashboard Cite

show abstract

“…PCNA is a nuclear cofactor for DNA polymerase y and is widely used as a marker of cell proliferation. PCNA expression in prostate cancer has been correlated with disease progression and negatively correlated with survival (31,32). High levels of E2F1 may provide tumor cells with a proliferative advantage by transcriptionally activating downstream targets involved in DNA synthesis and thus contribute to tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer

et al. 2006

View full text Add to dashboard Cite

Activation of E2F transcription factors, through disruption of the retinoblastoma (Rb) tumor-suppressor gene, is a key event in the development of many human cancers. Previously, we showed that homozygous deletion of Rb in a prostate tissue recombination model exhibits increased E2F activity, activation of E2F-target genes, and increased susceptibility to hormonal carcinogenesis. In this study, we examined the expression of E2F1 in 667 prostate tissue cores and compared it with the expression of the androgen receptor (AR), a marker of prostate epithelial differentiation, using tissue microarray analysis. We show that E2F1 expression is low in benign and localized prostate cancer, modestly elevated in metastatic lymph nodes from hormone-naïve patients, and significantly elevated in metastatic tissues from hormone-resistant prostate cancer patients (P = 0.0006). In contrast, strong AR expression was detected in benign prostate (83%), localized prostate cancer (100%), and lymph node metastasis (80%), but decreased to 40% in metastatic hormone-resistant prostate cancer (P = 0.004). Semiquantitative reverse transcription-PCR analysis showed elevated E2F1 mRNA levels and increased levels of the E2F-target genes dihyrofolate reductase and proliferating cell nuclear antigen in metastatic hormoneindependent prostate cancer cases compared with benign tissues. To identify a role of E2F1 in hormone-independent prostate cancer, we examined whether E2F1 can regulate AR expression. We show that exogenous expression of E2F1 significantly inhibited AR mRNA and AR protein levels in prostate epithelial cells. E2F1 also inhibited an AR promoterluciferase construct that was dependent on the transactivation domain of E2F1. Furthermore, using chromatin immunoprecipitation assays, we show that E2F1 and the pocket protein family members p107 and p130 bind to the AR promoter in vivo. Taken together, these results show that elevated E2F1, through its ability to repress AR transcription, may contribute to the progression of hormone-independent prostate cancer.

show abstract

“…Aggressive PCa was identified by the increased ratio of CB: SA together with pelvic lymph node metastasis (23). The MIB-1 staining index has been associated with PCa patient survival (27,28,33,41). DNA ploidy adds useful prognostic information for some PCa patients (19,32,(42)(43)(44).…”

Section: Discussionmentioning

confidence: 99%

Prediction of Aggressive Human Prostate Cancer by Cathepsin B

Sinha¹

2008

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. REPORT DATE 01-03-2008 REPORT TYPE 5e. TASK NUMBEREmail: sinha001@tc.umn.edu 5f. WORK UNIT NUMBER PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of Minnesota Minneapolis, MN 55455-2070 SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES14. ABSTRACT I received approval of the DOD-HSRRB in April, 2005 and began the study shortly after receiving approval. We are enclosing copies of published and accepted papers in the Anticancer Research. These papers address parts of both Specific Aims outlined in the project. I submitted an abstract of our accepted paper, "Cathepsin B Expression Indicates that Prostate Cancer is Similar in African-American and Caucasian Men" to the Department of Defense Prostate cancer research program meeting: Innovative Minds in Prostate Cancer Today (IMPACT). Our abstract was selected and accepted for presentation on September 5-6 meetings in Atlanta, GA. This is significant achievement for our work that started in April 2005. Our paper, "Heterogeneity of Cathepsin B and Stefin A Expression in Gleason Pattern 3+3 (score 6) Prostate Cancer Needle Biopsies" was published in Anticancer Research 27: 1407-1414, 2007. We showed that small foci of Gleason pattern 3+3 (histological score 6) tumors in needle biopsies have heterogeneous cathepsin B and stefin A immunostaining. We have shown that score 6 tumors are heterogeneous and some of the tumors had micrometastases. We have suggested that stratification of these tumors by cathepsin B and stefin A in relation to clinical data may assist in identification of aggressive cancer and treatment selection. SUBJECT TERMS Introduction:Cathepsin B (CB) is required for degradation of basement membrane and extracellular matrix proteins, including prostate cancer (PC) cell invasion to the subjacent stroma and extracellular matrix proteins followed by met...

show abstract

Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Cited by 33 publications

References 36 publications

Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas

Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas

Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer

Prediction of Aggressive Human Prostate Cancer by Cathepsin B

Contact Info

Product

Resources

About